The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
Volume 346:1770-1771 June 6, 2002 Number 23
NextNext

Sirolimus-Eluting Coronary Stents

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Morice, M.-C.
-PubMed Citation
The story of sirolimus began in 1975 on Easter Island, in the South Pacific, a remote, enigmatic place known for the prominent stone statues that punctuate its landscape. An actinomycete, Streptomyces hygroscopicus, cultured from a sample of the island's soil, was found to produce through natural fermentation a novel macrolide antibiotic with potent antifungal, immunosuppressive, and antimitotic activities. The generic name of the resulting drug is sirolimus (see Figure); it is also known as rapamycin, after Rapa Nui, the name given to Easter Island by its inhabitants.

Figure Removed (Available Only in the Full Text)
View larger version (54K):
[in this window]
[in a new window]
 
The Sirolimus-Eluting Stent, Shown with the Chemical Structure of the Molecule.

 
Twenty-five . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.